Skip to main content
    G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $9.61
    -0.62 (-6.06%)

    Market Cap: $622.97M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Ginkgo Bioworks Holdings (DNA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Ginkgo Bioworks Holdings are Gyre Therapeutics (GYRE), Neurogene (NGNE) and Sana Biotechnology (SANA). By market cap, Ginkgo Bioworks Holdings ranks 6th of the 13 companies on this page; Prime Medicine, Inc. Common Stock (PRME) is the largest at $949.85M.

    Peer Comparison

    DNA's revenue growth of -5.7% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Ginkgo Bioworks Holdings (DNA)$622.97MN/A6.1x-192.0%N/A-5.7%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Sana Biotechnology Inc (SANA)$605.26MN/AN/A0.0%-46.8%0.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Sagimet Biosciences Inc. Series A Common Stock (SGMT)$735.18MN/AN/A0.0%N/A0.0%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Solid Biosciences LLC (SLDB)$763.42MN/AN/A0.0%N/A-100.0%0.00%
    Climb Bio Inc (CLYM)$608.53MN/AN/A0.0%N/A0.0%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Orchestra BioMed Holdings Inc. (OBIO)$570.61MN/A14.7x-182.5%-97.0%-89.4%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Peer median$606.89MN/A3.8x0.0%-21.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Ginkgo Bioworks Holdings, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Sana Biotechnology Inc (SANA)
    Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
    SANA competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Sagimet Biosciences Inc. Series A Common Stock (SGMT)
    Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases...
    SGMT competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Solid Biosciences LLC (SLDB)
    Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States.
    SLDB competitors
    Climb Bio Inc (CLYM)
    Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
    CLYM competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors
    Orchestra BioMed Holdings Inc. (OBIO)
    Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases.
    OBIO competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors

    Frequently Asked Questions About DNA

    Who are Ginkgo Bioworks Holdings' main competitors?

    The companies most similar to Ginkgo Bioworks Holdings include Gyre Therapeutics (GYRE), Neurogene (NGNE), Sana Biotechnology (SANA), Regenxbio (RGNX) and Sagimet Biosciences Inc. Series A Common Stock (SGMT), listed from the closest match.

    Who is Ginkgo Bioworks Holdings' biggest competitor?

    Prime Medicine, Inc. Common Stock (PRME) is the largest of the similar companies at $949.85M; Gyre Therapeutics (GYRE) is the closest match by business profile, size, sector and industry.

    How does DNA stock compare with its competitors?

    DNA's P/S is 6.1x against a peer median of 3.8x; its net margin is -192.0% against a peer median of 0.0%.

    Which of Ginkgo Bioworks Holdings' competitors pays a higher dividend?

    Ginkgo Bioworks Holdings pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Ginkgo Bioworks Holdings bigger than its competitors?

    No. Ginkgo Bioworks Holdings is 6th by market cap among the 13 companies on this page; the largest is Prime Medicine, Inc. Common Stock (PRME) at $949.85M.